ABOUT US

About Us

Viewpoint Health is a boutique life sciences and healthcare consultancy that was founded on the principles of using evidence, strategy, and data science to maximize value and manage risk for our clients. Our deep expertise, skills, and knowledge in healthcare and life sciences along with our leading industry and academic affiliates allow us to bring focus and experience to how we manage our engagements and deliver insights and solutions to our life sciences and healthcare clients.

Viewpoint Health’s focus is to provide strategy, economic, and business consulting services to life sciences and healthcare companies as well as law firms on a wide range of matters related to pharmaceutical access. We have assisted clients on numerous matters regarding drug price reporting, commercial/government contracting, valuation, patient services, HEOR, and operational strategy. Our life sciences and healthcare clients include many of the largest global pharmaceutical, biotechnology, and medical device manufacturers, as well as numerous early-stage companies that are defining new models in the treatment and management of disease.

Our interdisciplinary staff and affiliates consist of professionals with advanced degrees in economics, statistics, public health, information technology, and business. We also work closely with a network of academic experts, key opinion leaders, and physicians at leading universities who help us develop and present state-of-the-art insight and solutions for our clients. Additionally, we have an extensive network of clinical and financial decision makers across the entire healthcare value chain including payers, providers, pharmacies, PBMs, and distribution partners that provide us with deep “real-time” insight regarding critical research questions.

The Team

Debjit A. Ghosh | Founder and CEO

Debjit (Deb) is the Founder and CEO of Viewpoint Health. He has over 25 years of experience in the pharmaceutical and life sciences industry has held positions in Managed Care, Market Research, and Brand Marketing. Deb currently assists Pharmaceutical, Biotechnology, and Medical Device companies on wide range of business strategy and risk related matters including organizational design, compliance, litigation support, operational consulting, valuation, health economics, and market access strategy. He also has testified and provided expert testimony on matters related to valuation and drug pricing and has performed damages analyses related to pharmaceutical pricing, allegations of off-label promotions, alleged violations of the anti-kickback statute and transaction/deal valuation matters including determinations of fair market value.

Deb has held senior leadership positions in life sciences consulting and at Merck & Company and Pharmacia/Pfizer. He is a frequent speaker at industry conferences in the United States and abroad and is a guest lecturer at Columbia Business School.

Education

  • Columbia Business School – M.B.A. in Finance and Economics
  • Columbia Business School – M.B.A. in Finance and Economics
  • Columbia University – M.S. in Epidemiology
  • Columbia University – M.A. in Applied Statistics
  • New York Medical College – M.S. in Health Management
  • Rutgers College – B.S. in Biological Sciences

Professional Associations

  • National Association of Certified Valuation Analysts (NACVA)
  • International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
  • International Health Economics Association (IHEA)

Raj Ghosh | Managing Director

Raj is a Managing Director at Viewpoint Health. He has over 15 years of experience specializing in the pharmaceutical and biotech industries where he focuses on providing clients with a wide range of business advisory services, which include optimizing company revenue, product distribution, drug price reporting, commercial/government contracting, compliance/risk assessments, and FMV valuations. He brings a unique combination of subject matter expertise, industry knowledge, and technical experience to each client opportunity.

Raj has spent the majority of his career in client-serving roles at Ernst & Young and KPMG.

Education and Professional Associations

  • Pace University – B.A. in Computer Science
  • Member of Association of Certified Fraud Examiners
  • Member of National Council for Prescription Drug Programs

Technical Experience:

  • Proficient in SAS, Tableau, Python and QlikView, and the MS suite of products including SQL Server
  • Developed and executed analytical solutions that deal with various types of transactional data (e.g., direct sales, indirect sales, rebates), pharmacy billing data, wholesaler EDI data (e.g., EDI 867 sales, EDI 844 chargeback, EDI 852 sales demand), and product returns data

 


Professor Frank R. Lichtenberg, PhD | Affiliate

Professor Frank Lichtenberg has been with the Columbia School of Business for 30 years, where he currently is a Courtney C. Brown Professor of Business for Finance and Economics, and a Courtney C. Brown Professor of Business for Healthcare and Pharmaceutical Management.

His research has examined how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. He has studied the impact of biomedical innovation on longevity and quality of life, the consequences of takeovers and LBOs for efficiency and employment, and the effect of computers on productivity in business and government organizations. A research associate of the National Bureau of Economic Research, Lichtenberg has received numerous research fellowships and grants, served as a consultant to a variety of private and public organizations and testified before Congress.

A prolific author, Professor Lichtenberg published his book, Corporate Takeovers and Productivity, and contributed the chapter Pharmaceutical Knowledge-Capital Accumulation and Longevity In Measuring Capital in the New Economy. Professor Lichtenberg’s writings have appeared a wide range of academic and industry journals such as PharmacoEconomics, International Journal of the Economics of Business, Nature Medicine and Forum for Health Economics & Policy.

Education

  • University of Chicago – B.A.
  • University of Pennsylvania – M.A. and Ph.D.

 


Winston Wong, PharmD | Payer Insights | Affiliate

Dr. Wong is the President of the W-Squared Group and an affiliate of Viewpoint. Winston provides key insights to bio-pharmaceutical companies and healthcare innovators in developing their value statements and payer positioning, and then assists with developing their launch strategies in the government and commercial marketplace.

Throughout his 30-year career in the pharmacy industry, he has been repeatedly recognized for his clinical and business innovations. During his past 17 years as the Associate Vice President of Pharmacy Management at CareFirst BlueCross BlueShield, from which he retired in the fall of 2013, he was responsible for the development, implementation, and administration of the prescription benefit, including formulary development, contracting, including the Medicare Part D prescription benefit. As part of the Part D benefit, he was instrumental in the development and implementation of a pharmacist driven Medication Therapy Management (MTM) program that has been recognized by CMS, and many national organizations.

Dr. Wong also implemented one of the first successful network-based oncology treatment pathway program, a Pay-for-Quality program in which oncologists collaborated with the health plan to comply with specific treatment pathways for specific cancer types while meeting specific clinical and quality metrics. Under Dr. Wong’s leadership, the model was expanded into rheumatology and gastroenterology.

Education

  • University of the Pacific – Ph.D.
  • University of Nebraska and Clinics – General Residency

Anthony Davino | Trade and Channel Strategy Leader | Affiliate

Mr. Davino is leading expert on pharmaceutical trade, pricing, and contracting matters. He’s a managing director with Route 3 Partners and works extensively with Viewpoint Health on matters relating to pharmaceutical trade strategy, pricing, and contracting. He has almost 20 years of direct pharmaceutical and biotechnology market experience and prior to founding Route 3 Partners held positions as a Managing Director with Apogenics, Inc., Vice President of Industry Relations with Armada Healthcare, and held numerous positions at Roche Labs including Trade Manager, Economic Analysis Manager, and Pricing Specialist. Mr. Davino has extensive experience with new and in-line pharmaceutical pricing matters, forecasting and modeling and gross-to-net management. In addition, he has regarded as one of the industry’s pre-eminent experts on pharmaceutical trade strategies, channel management, and distribution model development.